Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

被引：0
|
作者：
Ren, Yuhong [1 ]
Zhuang, Jingli [2 ]
Yuan, Ling [2 ]
Ji, Lili [1 ]
Ke, Yang [1 ]
Liu, Peng [3 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Hematol, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Sharman, Jeff
    Haioun, Corinne
    Kolibaba, Kathryn S.
    Chen, Andy
    Lamy, Thierry
    Jones, Surai
    Penuel, Elicia
    Lee, Calvin
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [42] Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
    Rita Assi
    Nohad Masri
    Iman Abou Dalle
    Jean El-Cheikh
    Hady Ghanem
    Ali Bazarbachi
    Clinical Hematology International, 2021, 3 (1) : 21 - 26
  • [43] Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma
    Hanno M. Witte
    Armin Riecke
    Thomas Mayer
    Tobias Bartscht
    Dirk Rades
    Hendrik Lehnert
    Hartmut Merz
    Sebastian Fetscher
    Harald Biersack
    Niklas Gebauer
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 129 - 136
  • [44] Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma
    Witte, Hanno M.
    Riecke, Armin
    Mayer, Thomas
    Bartscht, Tobias
    Rades, Dirk
    Lehnert, Hendrik
    Merz, Hartmut
    Fetscher, Sebastian
    Biersack, Harald
    Gebauer, Niklas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (01) : 129 - 136
  • [45] POLATUZUMAB VEDOTIN-RITUXIMAB-BENDAMUSTINE IN DIFFUSE LARGE CELL B LYMPHOMA: EXPERIENCE IN OUR CENTER
    Amarilla, Lanzas Irene Florencia
    Pimentel, Feliciano Ana Isabel
    Gracia, Piquer Raquel
    Rivas, Estaben Irene
    Ortiz, Lopez Alicia
    Gemperle, Ortiz Natalia
    Angos, Vazquez Sonia
    Dourdil, Sahun Maria Victoria
    Bonafonte, Arruga Maria Elena
    Martinez, Lazaro Beatriz
    Palomera, Bernal Luis Ramon
    HAEMATOLOGICA, 2020, 105 : 295 - 295
  • [46] Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
    Ruan, Jia
    Martin, Peter
    Furman, Richard R.
    Lee, Shing M.
    Cheung, Ken
    Vose, Julie M.
    LaCasce, Ann
    Morrison, Julia
    Elstrom, Rebecca
    Ely, Scott
    Chadburn, Amy
    Cesarman, Ethel
    Coleman, Morton
    Leonard, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : 690 - 697
  • [47] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
    Bartlett, Nancy L.
    Chen, Andy I.
    Kolibaba, Kathryn S.
    Lamy, Thierry
    Jones, Surai
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [48] Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma
    Teruhito Takakuwa
    Yusuke Okayama
    Hirohisa Nakamae
    Masatomo Kuno
    Yosuke Makuuchi
    Naonori Harada
    Hiroshi Okamura
    Mitsutaka Nishimoto
    Yasuhiro Nakashima
    Hideo Koh
    Masayuki Hino
    Annals of Hematology, 2022, 101 : 1609 - 1610
  • [49] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [50] COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA
    Bai, X.
    Shao, R.
    Zhen, B.
    Xia, Y.
    He, X.
    VALUE IN HEALTH, 2023, 26 (12) : S189 - S189
12345